Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 29 results.
User Information
Export Records
  1. 1.   Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib
  2. Kraft, Ira L.; Akshintala, Srivandana; Zhu, Yuelin; Lei, Haiyan; Derse-Anthony, Claudia; Dombi, Eva; Steinberg, Seth M.; Lodish, Maya; Waguespack, Steven G.; Kapustina, Oxana; Fox, Elizabeth; Balis, Frank M.; Merino, Maria J.; Meltzer, Paul S.; Glod, John W.; Shern, Jack F.; Widemann, Brigitte C.
  3. CLINICAL CANCER RESEARCH. 2018, Feb 15; 24(4): 753-765.
  1. 2.   Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers
  2. Butterfield, L. H.; Palucka, A. K.; Britten, C. M.; Dhodapkar, M. V.; Hakansson, L.; Janetzki, S.; Kawakami, Y.; Kleen, T. O.; Lee, P. P.; Maccalli, C.; Maecker, H. T.; Maino, V. C.; Maio, M.; Malyguine, A.; Masucci, G.; Pawelec, G.; Potter, D. M.; Rivoltini, L.; Salazar, L. G.; Schendel, D. J.; Slingluff, C. L.; Song, W. R.; Stroncek, D. F.; Tahara, H.; Thurin, M.; Trinchieri, G.; van Der Burg, S. H.; Whiteside, T. L.; Wigginton, J. M.; Marincola, F.; Khleif, S.; Fox, B. A.; Disis, M. L.
  3. Clinical Cancer Research. 2011, May; 17(10): 3064-3076.
  1. 3.   Plant Natural Products in Anticancer Drug Discovery
  2. Grothaus, P. G.; Cragg, G. M.; Newman, D. J.
  3. Current Organic Chemistry. 2010, Oct; 14(16): 1781-1791.
  1. 4.   The statistics of phase 0 trials
  2. Rubinstein, L. V.; Steinberg, S. M.; Kummar, S.; Kinders, R.; Parchment, R. E.; Murgo, A. J.; Tomaszewski, J. E.; Doroshow, J. H.
  3. Statistics in Medicine. 2010, May; 29(10): 1072-1076.
  1. 5.   Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
  2. Piekarz, R. L.; Frye, R.; Turner, M.; Wright, J. J.; Allen, S. L.; Kirschbaum, M. H.; Zain, J.; Prince, H. M.; Leonard, J. P.; Geskin, L. J.; Reeder, C.; Joske, D.; Figg, W. D.; Gardner, E. R.; Steinberg, S. M.; Jaffe, E. S.; Stetler-Stevenson, M.
  3. Journal of Clinical Oncology. 2009 27(32): 5410-5417.
  1. 6.   Incorporation of endothelial progenitor cells into the neovasculature of malignant glioma xenograft
  2. Zhang, H. R.; Chen, F. L.; Xu, C. P.; Ping, Y. F.; Wang, Q. L.; Liang, Z. Q.; Wang, J. M.; Bian, X. W.
  3. Journal of Neuro-Oncology. 2009 93(2): 165-174.
  1. 7.   Compressing drug development timelines in oncology using phase '0' trials
  2. Kummar, S.; Kinders, R.; Rubinstein, L.; Parchment, R. E.; Murgo, A. J.; Collins, J.; Pickeral, O.; Low, J.; Steinberg, S. M.; Gutierrez, M.; Yang, S.; Helman, L.; Wiltrout, R.; Tomaszewski, J. E.; Doroshow, J. H.
  3. Nature Reviews Cancer. 2007, Feb; 7(2): 131-139.
  1. 8.   Elevated K-ras activity with cholestyramine and lovastatin, but not konjac mannan or niacin in lung - Importance of mouse strain
  2. Calvert, R. J.; Tepper, S.; Kammouni, W.; Anderson, L. M.; Kritchevsky, D.
  3. Biochemical Pharmacology. 2006, Dec; 72(12): 1749-1755.
  1. 9.   Antibody-based inhibitors of HIV infection
  2. Choudhry, V.; Zhang, M. Y.; Dimitrova, D.; Prabakaran, P.; Dimitrov, A. S.; Fouts, T. R.; Dimitrov, D. S.
  3. Expert Opinion on Biological Therapy. 2006, MAY; 6(5): 523-531.
  1. 10.   TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer
  2. Cretney, E.; Shanker, A.; Yagita, H.; Smyth, M. J.; Sayers, T. J.
  3. Immunology and Cell Biology. 2006, FEB; 84(1): 87-98.
  1. 11.   Novel human monoclonal antibodies to insulin-like growth factor (IGH)-II that potently inhibit the IGF receptor type I signal transduction function
  2. Feng, Y.; Zhu, Z. Y.; Xiao, X. D.; Choudhry, V.; Barrett, J. C.; Dimitrov, D. S.
  3. Molecular Cancer Therapeutics. 2006, JAN; 5(1): 114-120.
  1. 12.   Carbohydrate array analysis of anti-Tn antibodies and lectins reveals unexpected specificities: Implications for diagnostic and vaccine development
  2. Manimala, J. C.; Li, Z. T.; Jain, A.; VedBrat, S.; Gildersleeve, J. C.
  3. Chembiochem. 2005, DEC; 6(12): 2229-2241.
  1. 13.   Antineoplastic agents. 445. Synthesis and evaluation of structural modifications of (Z)- and (E)-combretastatin A-4
  2. Pettit, G. R.; Rhodes, M. R.; Herald, D. L.; Hamel, E.; Schmidt, J. M.; Pettitt, R. K.
  3. Journal of Medicinal Chemistry. 2005, JUN 16; 48(12): 4087-4099.
  1. 14.   Design of a novel MRI compatible manipulator for image guided prostate interventions
  2. Krieger, A.; Susil, R. C.; Menard, C.; Coleman, J. A.; Fichtinger, G.; Atalar, E.; Whitcomb, L. L.
  3. IEEE Transactions on Biomedical Engineering. 2005, FEB; 52(2): 306-313.
  1. 15.   Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification
  2. Nellis, D. F.; Ekstrom, D. L.; Kirpotin, D. B.; Zhu, J. W.; Andersson, R.; Broadt, T. L.; Ouellette, T. F.; Perkins, S. C.; Roach, J. M.; Drummond, D. C.; Hong, K. L.; Marks, J. D.; Park, J. W.; Giardina, S. L.
  3. Biotechnology Progress. 2005, JAN-FEB; 21(1): 205-220.
  1. 16.   Effects of lymphocyte isolation and timing of processing on detection of CD127 expression on T cells in human immunodeficiency virus-infected patients
  2. Higgins, J.; Metcalf, J. A.; Stevens, R. A.; Baseler, M.; Nason, M. C.; Lane, H. C.; Sereti, I.
  3. Clinical and Diagnostic Laboratory Immunology. 2005, JAN; 12(1): 228-230.
  1. 17.   Replacing acid alpha-glucosidase in Pompe disease: Recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers
  2. Raben, N.; Fukuda, T.; Gilbert, A. L.; de Jong, D.; Thurberg, B. L.; Mattaliano, R. J.; Meikle, P.; Hopwood, J. J.; Nagashima, K.; Nagaraju, K.; Plotz, P. H.
  3. Molecular Therapy. 2005, JAN; 11(1): 48-56.
  1. 18.   Efficacy and safety of generic amphotericin B in experimental pulmonary aspergillosis
  2. Petraitis, V.; Petraitiene, R.; Lin, P. X.; Calis, K.; Kelaher, A. M.; Muray, H. A.; Mya-San, C.; Mickiene, D.; Bacher, J.; Walsh, T. J.
  3. Antimicrobial Agents and Chemotherapy. 2005 49(4): 1642-1645.
  1. 19.   7-hydroxystaurosporine (UCN-01) inhibition of Akt Thr(308) but not Ser(473) phosphorylation: A basis for decreased insulin-stimulated glucose transport
  2. Kondapaka, S. B.; Zarnowski, M. J.; Yver, D. R.; Sausville, E. A.; Cushman, S. W.
  3. Clinical Cancer Research. 2004, NOV 1; 10(21): 7192-7198.
  1. 20.   Schedule-dependent inhibition of hypoxia-inducible factor-1 alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts
  2. Rapisarda, A.; Zalek, J.; Hollingshead, M.; Braunschweig, T.; Uranchimeg, B.; Bonomi, C. A.; Borgel, S. D.; Carter, J. P.; Hewitt, S. M.; Shoemaker, R. H.; Melillo, G.
  3. Cancer Research. 2004, OCT 1; 64(19): 6845-6848.
  1. 21.   SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity. Part 2: Efficacy evaluations
  2. Alley, M. C.; Hollingshead, M. G.; Pacula-Cox, C. M.; W, W. R.; Hartley, J. A.; Howard, P. W.; Gregson, S. J.; Thurston, D. E.; Sausville, E. A.
  3. Cancer Research. 2004, SEP 15; 64(18): 6700-6706.
  1. 22.   The experimental antitumor agents Phortress and Doxorubicin are equiactive against human-derived breast carcinoma xenograft models
  2. Fichtner, I.; Monks, A.; Hose, C.; Stevens, M. F. G.; Bradshaw, T. D.
  3. Breast Cancer Research and Treatment. 2004, SEP; 87(1): 97-107.
  1. 23.   Marine natural products and related compounds in clinical and advanced preclinical trials
  2. Newman, D. J.; Cragg, G. M.
  3. Journal of Natural Products. 2004, AUG; 67(8): 1216-1238.
  1. 24.   Improved breadth and potency of an HIV-1-neutralizing human single-chain antibody by random mutagenesis and sequential antigen panning
  2. Zhang, M. Y.; Shu, Y. U.; Rudolph, D.; Prabakaran, P.; Labrijn, A. F.; Zwick, M. B.; Lal, R. B.; Dimitrov, D. S.
  3. Journal of Molecular Biology. 2004 335(1): 209-219.
  1. 25.   Action of Anti-HIV drugs and resistance: Reverse transcriptase inhibitors and protease inhibitors
  2. Imamichi, T.
  3. Current Pharmaceutical Design. 2004 10(32): 4039-4053.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel